Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SCTV 01E

Next Previous
X
Search
Drug Profile

SCTV 01E

Alternative Names: COVID-19 Alpha/Beta/Delta/Omicron Variants S-Trimer Vaccine -; SCTV-01E

Latest Information Update: 23 Feb 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sinocelltech
  • Class COVID-19 vaccines; Subunit vaccines; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II COVID 2019 infections

Most Recent Events

  • 09 Feb 2024 Sinocelltech withdraws a phase-II trial for COVID-2019 infections (Prevention, In volunteers) (IM, Injection), prior to enrolment as there was not a need of this trial any more (NCT05308602)
  • 15 Jan 2024 Sinocelltech completes a phase II trial in COVID-2019 infections (Prevention, In adults, In children, In the elderly) in China (IM) (NCT05652543)
  • 13 Jan 2023 Sinocelltech plans a phase III trial for COVID-19 infections (Prevention, In adults, In the elderly) (IM, Injection) in January 2023 (NCT05683561)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top